MDxHealth SA (MDXH) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
YD Bio (YDES) has outperformed MDxHealth SA (MDXH) over the past year, losing 66.1% versus a loss of 87.2%. YD Bio is the larger company by market cap ($490.9 million vs $54.9 million), about 8.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXH | YDES |
|---|---|---|
| Share price | $0.5754 | $6.93 |
| Market cap | $54.90M | $490.90M |
| 1-day change | -0.88% | +20.48% |
| YTD return | -83.74% | -52.50% |
| 1-year return | -87.16% | -66.06% |
| EPS (TTM) | $-0.70 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.33 | $22.00 |
| 52-week low | $0.40 | $1.70 |
| Distance from 52-week high | -89.20% | -68.50% |
| Analyst consensus | none | — |
| Avg. price target upside | +212.83% | — |
| Average volume | 5.69M | 284.92K |
| Shares outstanding | 95.42M | 70.83M |
| Employees | 364 | 13 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YD Bio is about 8.9 times larger than MDxHealth SA by market value ($490.90M vs $54.90M).
- YDES has outperformed MDXH by 21.1 percentage points over the past year.
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Health Care · Medical Specialities · 364 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Health Care · Medical Specialities · 13 employees
MDXH vs YDES FAQ
Which is bigger, MDxHealth SA or YD Bio?
YD Bio (YDES) is larger, with a market capitalization of $490.90M compared with $54.90M for MDxHealth SA (MDXH).
Which stock has performed better over the past year, MDXH or YDES?
YDES returned -66.06% over the past 12 months, compared with -87.16% for MDXH (price return, excluding dividends). Past performance does not predict future results.
Are MDxHealth SA and YD Bio in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.